Related Experiment Video
Updated: Jun 4, 2026

Fertility Preservation Through Oocyte Vitrification: Clinical and Laboratory Perspectives
Published on: September 16, 2021
When to start an aromatase inhibitor: now or later?
1University Department of Surgery, Western Infirmary, Dumbarton Road, Glasgow, Scotland, UK. j.c.doughty@clinmed.gla.ac.uk
Abstract:
Among women who have undergone surgery for breast cancer, the risk of recurrence, especially distant metastases, peaks 1-2 years postsurgery. Recent clinical trial evidence suggests that initial adjuvant therapy with an aromatase inhibitor (AI) can reduce this early risk of recurrence. According to the recently updated St Gallen consensus statement, initial AI therapy is the preferred strategy for adjuvant endocrine therapy in postmenopausal women with hormone receptor-positive breast cancer.
Related Concept Videos
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Hormonal Control of the Ovarian Cycle
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Drug Therapy
Antianxiety Medications
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Treatment Resistant Cancers
